ClinicalTrials.gg
Not yet recruitingNCT07941609PATAGONIAUpdated Nov 17, 2026

A Study to Investigate the Efficacy and Safety of Dato-DXd-based Combinations in Participants With TROP2 NMR+ NSCLC

A Phase 2 interventional study of Dato-DXd and Durvalumab in Non-small Cell Lung Cancer (NSCLC), sponsored by AstraZeneca. Not yet recruiting at 87 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing datopotamab deruxtecan in Carcinoma, Non-Small-Cell Lung — 8 open to participants now, 20 under way, 9 of them phase 3. datopotamab deruxtecan · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
13th of 22
250 · median 273
Started
2026
with 1 other
Phase 2
8 of 22
4 open now
Primary completion
2028-12
later than 12 of 19 live
Registered
21st of 22
by date
Lead sponsor
12 of 22
AstraZeneca

Among the 22 studies testing datopotamab deruxtecan in Carcinoma, Non-Small-Cell Lung, this one is the 13th largest by planned enrollment, is one of 2 that started in 2026, is one of 8 in phase 2, reaches primary completion later than 12 of the 19 other live ones, and was the 21st registered.

Carcinoma, Non-Small-Cell Lung

7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

8 of the 22 studies testing datopotamab deruxtecan in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About datopotamab deruxtecan

datopotamab deruxtecan: first FDA approval 2025 (DATROWAY), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing datopotamab deruxtecan in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

Phase II, open-label, multicentre, multi-cohort platform study to determine the efficacy and safety of Datopotamab Deruxtecan (Dato-DXd)-based combinations for the treatment of TROP2 NMR+ NSCLC.

Read the detailed description

This is a Phase II, open-label, multicentre, multi-cohort platform study to determine the efficacy and safety of Datopotamab Deruxtecan (Dato-DXd)-based combinations for the treatment of TROP2 NMR+ NSCLC.

This study is designed as non-comparative.

Participants will be randomised to Treatment A or B.

In the module 1 of this study, Dato-DXd-based regimens will be assessed in participants with non-AGA NSCLC whose tumours have been prospectively identified as TROP2 NMR+.

The proposed primary objectives are to assess the efficacy of Dato-DXd combined with durvalumab and carboplatin and Dato-DXd combined with durvalumab in terms of PFS per RECIST 1.1 as assessed by the investigator.

Participants in both treatment groups will receive study treatment medicines until investigator-assessed radiological progression per RECIST 1.1, unacceptable toxicity, withdrawal of consent, or an intervention discontinuation criterion is met. There is no maximum limit to the number of cycles of Dato-DXd and/or durvalumab that a participant in either treatment group can receive. The maximum treatment for carboplatin is 4 cycles.

The study will be conducted in several countries worldwide.

03

Conditions studied

  • Non-small Cell Lung Cancer (NSCLC)

Keywords

  • TROP2 NMR-positive NSCLC,
  • Dato-DXd,
  • durvalumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant must be ≥ 18 years of age at the time of signing the ICF.
  2. documented NSCLC that:

    1. Has documented non-squamous histology
    2. Is TROP2 NMR positive
    3. Documented lack of sensitising EGFR mutation, as well as ALK and ROS1 rearrangements on tumour tissue.
  3. Stage IIIB or IIIC disease not amenable to surgical resection or definitive chemoradiation, or Stage IV NSCLC at the time of randomisation, as per the American Joint Committee on Cancer Staging System, 9th Edition.
  4. The PS of 0 to 2.
  5. Known tumour status.
  6. Minimum of 12 weeks.
  7. Provision of acceptable FFPE tumour sample from a lesion not previously irradiated.
  8. At least 1 lesion, not previously irradiated, that qualifies as a 1.1 target lesion at baseline.
  9. Adequate bone marrow reserve and organ function.
  10. use by participants or participant partners.
  11. Capable of giving signed .
  12. Provision of signed and dated optional informed consent.

Exclusion criteria

EXCLUSION CRITERIA:

  1. As judged by the investigator, any evidence of diseases, chronic diverticulitis or previous complicated diverticulitis, or history of allogenic organ transplant, which, in the investigator's opinion, makes it undesirable for the participant to participate in the study or that would jeopardise compliance with the protocol.
  2. History of another primary except for malignancy treated with curative intent with no known active disease within 3 years before the first dose of study intervention and of low potential risk for recurrence, adequately resected basal cell carcinoma of the skin or squamous cell carcinoma of the skin, lentigo maligna that has undergone potentially curative therapy, or adequately treated in situ disease without evidence of disease.
  3. Squamous histology or mixed SCLC and NSCLC, or sarcomatoid variant of NSCLC, or lung neuroendocrine tumours .
  4. Has documented tumour genomic alterations in EGFR, ALK, ROS1, NTRK, BRAF V600E, RET, MET exon 14, or any other actionable driver oncogenes for which there are locally approved and available targeted therapies.

    Note: Participants whose tumours harbour KRAS mutations are eligible for the study

  5. Persistent toxicities caused by previous anti-cancer therapy, excluding alopecia or vitiligo, not yet improved to Grade ≤ 1 or baseline.
  6. Active or prior documented , connective tissue or inflammatory disorders, autoimmune pneumonitis, or autoimmune myocarditis.
  7. Spinal cord compression or , unless asymptomatic, stable, and not requiring treatment with or anticonvulsants for at least 7 days prior to randomisation.
  8. History of or .
  9. corneal disease.
  10. Has active or uncontrolled or infection.
  11. Known infection that is not well controlled.
  12. Uncontrolled infection requiring systemic antibiotics, antivirals, or antifungals, suspected infections or inability to rule out infections.
  13. Known to have active tuberculosis infection.
  14. Mean resting > 470 ms, regardless of gender, obtained from triplicate 12-lead ECGs performed at screening.
  15. Uncontrolled or significant cardiac disease.
  16. History of ILD/pneumonitis.
  17. Has clinically severe pulmonary function compromised.
  18. Prior exposure to:

    1. Any agent, including ADC, containing a chemotherapeutic agent targeting topoisomerase I
    2. Chemotherapy or any other systemic therapy for first-line Stage IIIB, IIIC, or IV NSCLC
    3. TROP2-targeted therapy
    4. Chloroquine/hydroxychloroquine without an adequate treatment .
  19. Participants who have received any prior adjuvant, , or definitive chemoradiation for early stage disease (Stage I to III) are eligible, provided they meet the protocol-defined conditions.
  20. Current or prior use of medication within 14 days before the first dose of study intervention.
  21. Any concurrent anti-cancer treatment.
  22. Any concomitant medication known to be associated with Torsades de Pointes.
  23. Receipt of live, attenuated vaccine within 30 days prior to the first dose of study intervention.
  24. Received prior radiotherapy to the brain within 2 weeks of start of study intervention or received palliative radiotherapy to the chest within 4 weeks of start of study intervention or has ongoing radiation-related toxicities requiring corticosteroids.
  25. Major surgical procedure or significant traumatic injury within ≤ 4 weeks of the first dose of study intervention or an anticipated need for major surgery during the study.
  26. Participation in another clinical study with a study intervention or medicinal device administered in the last 4 weeks prior to randomisation or concurrent participation in another clinical study.
  27. Participants with a known history of severe reactions to study intervention or any of these products.
  28. Participants with a known history of severe hypersensitivity reactions to other monoclonal antibodies.
  29. Allocation to a stratum that has reached the cap.
  30. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).
  31. Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.
  32. For females only: Is pregnant (confirmed with positive serum pregnancy test), or breastfeeding, or planning to become pregnant.
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
250 participants (estimated)

Study arms

  • Experimental
    Treatment A

    Participants will receive Dato-DXd and durvalumab Q3W on Day 1 of every 21-day cycle.

    Drug: Dato-DXd · Drug: Durvalumab

  • Experimental
    Treatment B

    Participants will receive Dato-DXd, durvalumab, and carboplatin Q3W on Day 1 of every 21-day cycle for the first 4 cycles, followed by Dato-Dxd and durvalumab Q3W

    Drug: Dato-DXd · Drug: Durvalumab · Drug: Carboplatin

Interventions

  • Treatment A/B: Dato-DXd as IV infusion.

    Also known as: Datopotamab Deruxtecan

  • Treatment A/B: Durvalumab as IV infusion

  • Treatment B: Carboplatin as IV infusion

06

What researchers measure

Primary outcomes

  1. PFS as assessed by investigator on Treatment A

    PFS is defined as time from date of first dose of any study treatment until progression per RECIST 1.1 as assessed by the investigator at the local site or death due to any cause. Primary measure of interest is the median PFS.

    Time frame: Date of first dose of study intervention until disease progression per RECIST 1.1 or death from any cause, or end of study whichever occurs first, up to approximately 30 months

  2. PFS as assessed by investigator on Treatment B

    PFS is defined as time from date of first dose of any study treatment until progression per RECIST 1.1 as assessed by the investigator at the local site or death due to any cause. Primary measure of interest is the median PFS.

    Time frame: Date of first dose of study intervention until disease progression per RECIST 1.1 or death from any cause, or end of study whichever occurs first, up to approximately 30 months

Secondary outcomes

  1. Objective Response rate (ORR) in each treatment arm

    ORR is defined as the proportion of participants who have a confirmed response (CR or PR), as determined by the investigator at local site per RECIST 1.1. For each study treatment group, the primary measure of interest is the estimate of ORR.

    Time frame: Date of first dose of study intervention until disease progression per RECIST 1.1 or death from any cause, or end of study whichever occurs first, up to approximately 30 months

  2. Duration of response (DoR) in each treatment arm

    DoR is defined as the time from the date of first documented confirmed response until the date of documented progression per RECIST 1.1 as assessed by the investigator at the local site or death due to any cause. For each study treatment group, the primary measure of interest is the median DoR.

    Time frame: Date of first dose of study intervention until disease progression per RECIST 1.1 or death from any cause, or end of study whichever occurs first, up to approximately 30 months

Other outcomes

  1. Safety as measured by the number of patients with at least one adverse event (AE), by study treatment

    Proportion of patients with at least one AE

    Time frame: Date of first dose of study intervention until earliest of 90 days after study treatment discontinuation, death or end of study, up to approximately 30 months

07

Study locations

87 sites
  • Research Site
    Irvine, California 92618, United States
  • Research Site
    Oakland, California 94612, United States
  • Research Site
    Golden, Colorado 80401, United States
  • Research Site
    New Haven, Connecticut 06519, United States
  • Research Site
    Miami, Florida 33170, United States
  • Research Site
    Tampa, Florida 33612, United States
  • Research Site
    Atlanta, Georgia 30318, United States
  • Research Site
    Peoria, Illinois 61637, United States
  • Research Site
    Greer, South Carolina 29650, United States
  • Research Site
    Greer, South Carolina 29651, United States
  • Research Site
    Sugar Land, Texas 77479, United States
  • Research Site
    Salt Lake City, Utah 84112, United States
  • Research Site
    Morgantown, West Virginia 26506, United States
  • Research Site
    Ciudad Autonoma Buenos Aires, 1405, Argentina
  • Research Site
    Ciudad de Buenos Aires, C1427ARO, Argentina
  • Research Site
    La Rioja, 5300, Argentina
  • Research Site
    Rosario, 2000, Argentina
  • Research Site
    Rosario, S2000KZE, Argentina
  • Research Site
    San Juan, 5400, Argentina
  • Research Site
    Viedma, R8500ACE, Argentina
  • Research Site
    Adelaide, 5000, Australia
  • Research Site
    Bedford Park, 5042, Australia
  • Research Site
    Southport, 4215, Australia
  • Research Site
    Waratah, 2298, Australia
  • Research Site
    Woodville, 5011, Australia
  • Research Site
    Blumenau, 89010-340, Brazil
  • Research Site
    Curitiba, 80810-050, Brazil
  • Research Site
    Ijuí, 98700-000, Brazil
  • Research Site
    Porto Alegre, 90610-000, Brazil
  • Research Site
    Porto Alegre, 91350200, Brazil
  • Research Site
    Rio de Janeiro, 22281-100, Brazil
  • Research Site
    Salvador, 40170-110, Brazil
  • Research Site
    Santa Maria, 97015-450, Brazil
  • Research Site
    São Paulo, 01246-000, Brazil
  • Research Site
    São Paulo, 01509-900, Brazil
  • Research Site
    São Paulo, 03102-006, Brazil
  • Research Site
    Teresina, 64049-200, Brazil
  • Research Site
    Vitória, 29043-260, Brazil
  • Research Site
    Edmonton, Alberta T6G 1Z2, Canada
  • Research Site
    Brampton, Ontario L6R 3J7, Canada
  • Research Site
    Toronto, Ontario M4N 3M5, Canada
  • Research Site
    Montreal, Quebec H3T 1M5, Canada
  • Research Site
    Beijing, 100191, China
  • Research Site
    Beijing, 100730, China
  • Research Site
    Changchun, 130021, China
  • Research Site
    Changsha, 410013, China
  • Research Site
    Chengdu, 610041, China
  • Research Site
    Chongqing, 400030, China
  • Research Site
    Guangzhou, 510000, China
  • Research Site
    Hangzhou, 310009, China
  • Research Site
    Harbin, 150081, China
  • Research Site
    Nanchang, 330000, China
  • Research Site
    Nanning, 530021, China
  • Research Site
    Shandong, China
  • Research Site
    Shanghai, 200030, China
  • Research Site
    Shanghai, 200032, China
  • Research Site
    Tianjin, 300051, China
  • Research Site
    Wuhan, 430022, China
  • Research Site
    Yangzhou, 225001, China
  • Research Site
    Zhengzhou, 450000, China
  • Research Site
    Zhengzhou, 450008, China
  • Research Site
    Marseille, 13273, France
  • Research Site
    Nice, 06000, France
  • Research Site
    Paris, 75005, France
  • Research Site
    Paris, 75014, France
  • Research Site
    Pessac, 33604, France
  • Research Site
    Villefranche-sur-Saône, 69655, France
  • Research Site
    Lucca, 55100, Italy
  • Research Site
    Orbassano, 10043, Italy
  • Research Site
    Parma, Italy
  • Research Site
    Rozzano, 20089, Italy
  • Research Site
    Torrette, 60126, Italy
  • Research Site
    Verona, 37126, Italy
  • Research Site
    Lodz, 93-338, Poland
  • Research Site
    Lodz, 93-513, Poland
  • Research Site
    Przemyśl, 37-700, Poland
  • Research Site
    Warsaw, 00-124, Poland
  • Research Site
    Singapore, 119228, Singapore
  • Research Site
    Singapore, 168583, Singapore
  • Research Site
    Singapore, 217562, Singapore
  • Research Site
    Singapore, 308433, Singapore
  • Research Site
    Cheongju-si, 28644, South Korea
  • Research Site
    Jinju, 660-702, South Korea
  • Research Site
    Seongnam-si, 13620, South Korea
  • Research Site
    Seoul, 120-749, South Korea
  • Research Site
    Seoul, 5505, South Korea
  • Research Site
    Suwon, 16247, South Korea
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Dec 2028, 24 months later.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's planned 24 months is below that.

Counting every sponsor, half of 1,046 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2026
First posted
Nov 17, 2026
StartEst.
Nov 30, 2026
Primary completionEst.
Dec 16, 2028
CompletionEst.
Dec 22, 2028
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07941609
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Nov 17, 2026
Start date
Nov 30, 2026 (estimated)
Primary completion
Dec 16, 2028 (estimated)
Completion
Dec 22, 2028 (estimated)
Last update
Nov 17, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Datopotamab deruxtecan

Start the discussion